PML: An emerging tumor suppressor and a target with therapeutic potential

Eric L. Reineke, Huang Ying Kao

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)

Abstract

Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types of cancers show decreased expression of PML protein, though the mechanisms leading to this down-regulation are unknown. Decreased expression of PML can result in loss of cell cycle control and prevention of apoptosis and is likely a key event in the promotion of oncogenesis. Many of these effects are due to changes in the transcriptional profile of the cell as a result of decreased size and number of PML nuclear bodies. Several mouse studies confirm the contribution of PML to oncogenesis and cancer progression. It is important to not only further define a role for PML as a tumor suppressor, but also to begin to develop strategies to target PML therapeutically.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalCancer Therapy
Volume7
Issue numberISSUE A
Publication statusPublished - 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'PML: An emerging tumor suppressor and a target with therapeutic potential'. Together they form a unique fingerprint.

Cite this